$599

Lilly’s novel uRAI lispro contains citrate and treprostinil

An ADA abstract titled “A Novel Formulation of Insulin Lispro Containing Citrate and Treprostinil Shows Faster Absorption and Improved Postprandial Glucose Excursions vs. Humalog in Patients with T1DM” will be presented by Lilly at the General Poster Session on June 10, 2017.

This content is for Read Less members only.
Register
Already a member? Log in here